| Characteristic | R&D expenses in billion Japanese yen |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
April 2024
More information
Region
Japan
Survey time period
fiscal year 2014 to 2023; the company's fiscal year starts on April 1 of the stated year and ends on March 31 of the following year
Special properties
consolidated data
Supplementary notes
Astellas Pharma Inc. has adopted International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2014. Figures up to fiscal year ended March 31 2014, are based on Japanese generally accepted accounting principles (J-GAAP).
Figures prior to FY 2021 come from the previous reporting.
100 Japanese yen equal 0.64 U.S. dollars or 0.6 euros as of May 2024.Â
Citation formats
